Integrative meta-analysis of differential gene expression in acute myeloid leukemia

PLoS ONE

Volumn 5, Issue 3, 2010, Pages

  Miller, Brady G ^a   Stamatoyannopoulos, John A ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CLINICAL TRIAL; CYTOGENETICS; FUNCTIONAL GENOMICS; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; GENE REPLICATION; GENETIC ANALYSIS; GENETIC ASSOCIATION; HUMAN; META ANALYSIS; PROGNOSIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SYSTEMATIC REVIEW; CHROMOSOME MAP; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; GENETIC DATABASE; GENETICS; METABOLISM;

CHROMOSOME MAPPING; CLUSTER ANALYSIS; CYTOGENETICS; DATABASES, GENETIC; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 77949715448     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009466     Document Type: Article

References (96)

1. Wheatley K, Burnett AK, Goldstone AH, Gray RG, Hann IM, et al. (1999) A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 107: 69-79.
2. Schlenk RF, Dohner K (2009) Impact of new prognostic markers in treatment decisions in acute myeloid leukemia. Curr Opin Hematol 16: 98-104.
3. Wouters BJ, Lowenberg B, Delwel R (2009) A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 113: 291-298.
4. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, et al. (1999) Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 286: 531-537.
5. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, et al. (2001) Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci U S A 98: 1124-1129.
6. Okutsu J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, et al. (2002) Prediction of chemosensitivity for patients with acute myeloid leukemia, according to expression levels of 28 genes selected by genome-wide complementary DNA microarray analysis. Mol Cancer Ther 1: 1035-1042.
7. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, et al. (2002) Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci U S A 99: 10008-10013.
8. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, et al. (2003) Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 37: 149-158.
9. Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, et al. (2003) Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 37: 396-405.
10. Yagi T, Morimoto A, Eguchi M, Hibi S, Sako M, et al. (2003) Identification of a gene expression signature associated with pediatric AML prognosis. Blood 102: 1849-1856.
11. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, et al. (2004) Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 350: 1605-1616.
12. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, et al. (2004) Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes. Blood 104: 2646-2654.
13. Neben K, Tews B, Wrobel G, Hahn M, Kokocinski F, et al. (2004) Gene expression patterns in acute myeloid leukemia correlate with centrosome aberrations and numerical chromosome changes. Oncogene 23: 2379-2384.
14. Ross ME, Mahfouz R, Onciu M, Liu HC, Zhou X, et al. (2004) Gene expression profiling of pediatric acute myelogenous leukemia. Blood 104: 3679-3687.
15. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, et al. (2004) Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350: 1617-1628.
16. Vey N, Mozziconacci MJ, Groulet-Martinec A, Debono S, Finetti P, et al. (2004) Identification of new classes among acute myelogenous leukaemias with normal karyotype using gene expression profiling. Oncogene 23: 9381-9391.
17. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, et al. (2005) Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood 106: 899-902.
18. Gutierrez NC, Lopez-Perez R, Hernandez JM, Isidro I, Gonzalez B, et al. (2005) Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia. Leukemia 19: 402-409.
19. Haferlach T, Kohlmann A, Schnittger S, Dugas M, Hiddemann W, et al. (2005) AML M3 and AML M3 variant each have a distinct gene expression signature but also share patterns different from other genetically defined AML subtypes. Genes Chromosomes Cancer 43: 113-127.
20. Heuser M, Wingen LU, Steinemann D, Cario G, von Neuhoff N, et al. (2005) Gene-expression profiles and their association with drug resistance in adult acute myeloid leukemia. Haematologica 90: 1484-1492.
21. Neben K, Schnittger S, Brors B, Tews B, Kokocinski F, et al. (2005) Distinct gene expression patterns associated with FLT3- and NRAS-activating mutations in acute myeloid leukemia with normal karyotype. Oncogene 24: 1580-1588.
22. Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, et al. (2005) Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 106: 3747-3754.
23. Gal H, Amariglio N, Trakhtenbrot L, Jacob-Hirsh J, Margalit O, et al. (2006) Gene expression profiles of AML derived stem cells; similarity to hematopoietic stem cells. Leukemia 20: 2147-2154.
24. Lee S, Chen J, Zhou G, Shi RZ, Bouffard GG, et al. (2006) Gene expression profiles in acute myeloid leukemia with common translocations using SAGE. Proc Natl Acad Sci U S A 103: 1030-1035.
25. Radmacher MD, Marcucci G, Ruppert AS, Mrozek K, Whitman SP, et al. (2006) Independent confirmation of a prognostic gene-expression signature in adult acute myeloid leukemia with a normal karyotype: a Cancer and Leukemia Group B study. Blood 108: 1677-1683.
26. Wilson CS, Davidson GS, Martin SB, Andries E, Potter J, et al. (2006) Gene expression profiling of adult acute myeloid leukemia identifies novel biologic clusters for risk classification and outcome prediction. Blood 108: 685-696.
27. Bullinger L, Rucker FG, Kurz S, Du J, Scholl C, et al. (2007) Gene-expression profiling identifies distinct subclasses of core binding factor acute myeloid leukemia. Blood 110: 1291-1300.
28. Eisele L, Klein-Hitpass L, Chatzimanolis N, Opalka B, Boes T, et al. (2007) Differential expression of drug-resistance-related genes between sensitive and resistant blasts in acute myeloid leukemia. Acta Haematol 117: 8-15.
29. Park MH, Cho SA, Yoo KH, Yang MH, Ahn JY, et al. (2007) Gene expression profile related to prognosis of acute myeloid leukemia. Oncol Rep 18: 1395-1402.
30. Stapnes C, Ryningen A, Hatfield K, Oyan AM, Eide GE, et al. (2007) Functional characteristics and gene expression profiles of primary acute myeloid leukaemia cells identify patient subgroups that differ in susceptibility to histone deacetylase inhibitors. Int J Oncol 31: 1529-1538.
31. Wouters BJ, Jorda MA, Keeshan K, Louwers I, Erpelinck-Verschueren CA, et al. (2007) Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1. Blood 110: 3706-3714.
32. Stirewalt DL, Meshinchi S, Kopecky KJ, Fan W, Pogosova-Agadjanyan EL, et al. (2008) Identification of genes with abnormal expression changes in acute myeloid leukemia. Genes Chromosomes Cancer 47: 8-20.
33. Mullighan CG, Kennedy A, Zhou X, Radtke I, Phillips LA, et al. (2007) Pediatric acute myeloid leukemia with NPM1 mutations is characterized by a gene expression profile with dysregulated HOX gene expression distinct from MLL-rearranged leukemias. Leukemia 21: 2000-2009.
34. Larsson O, Sandberg R (2006) Lack of correct data format and comparability limits future integrative microarray research. Nat Biotechnol 24: 1322-1323.
35. Cahan P, Rovegno F, Mooney D, Newman JC, St Laurent G, 3rd, et al. (2007) Meta-analysis of microarray results: challenges, opportunities, and recommendations for standardization. Gene 401: 12-18.
36. Griffith OL, Melck A, Jones SJ, Wiseman SM (2006) Meta-analysis and meta-review of thyroid cancer gene expression profiling studies identifies important diagnostic biomarkers. J Clin Oncol 24: 5043-5051.
37. Chan SK, Griffith OL, Tai IT, Jones SJ (2008) Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 17: 543-552.
38. Smid M, Dorssers LC, Jenster G (2003) Venn Mapping: clustering of heterologous microarray data based on the number of co-occurring differentially expressed genes. Bioinformatics 19: 2065-2071.
39. Cahan P, Ahmad AM, Burke H, Fu S, Lai Y, et al. (2005) List of lists-annotated (LOLA): a database for annotation and comparison of published microarray gene lists. Gene 360: 78-82.
40. Newman JC, Weiner AM (2005) L2L: a simple tool for discovering the hidden significance in microarray expression data. Genome Biol 6: R81.
41. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, et al. (2006) Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 84: 77-92.
42. Makatsori E, Lamari FN, Theocharis AD, Anagnostides S, Hjerpe A, et al. (2003) Large matrix proteoglycans, versican and perlecan, are expressed and secreted by human leukemic monocytes. Anticancer Res 23: 3303-3309.
43. Kanaoka Y, Urade Y (2003) Hematopoietic prostaglandin D synthase. Prostaglandins Leukot Essent Fatty Acids 69: 163-167.
44. Guillemin R (2005) Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol 184: 11-28.
45. Joshi N, Johnson LL, Wei WQ, Abnet CC, Dong ZW, et al. (2006) Gene expression differences in normal esophageal mucosa associated with regression and progression of mild and moderate squamous dysplasia in a high-risk Chinese population. Cancer Res 66: 6851-6860.
46. Huang H, Hara A, Homma T, Yonekawa Y, Ohgaki H (2005) Altered expression of immune defense genes in pilocytic astrocytomas. J Neuropathol Exp Neurol 64: 891-901.
47. Slifman NR, Loegering DA, McKean DJ, Gleich GJ (1986) Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol 137: 2913-2917.
48. Yang D, Rosenberg HF, Chen Q, Dyer KD, Kurosaka K, et al. (2003) Eosinophil-derived neurotoxin (EDN), an antimicrobial protein with chemotactic activities for dendritic cells. Blood 102: 3396-3403.
49. Domachowske JB, Bonville CA, Dyer KD, Rosenberg HF (1998) Evolution of antiviral activity in the ribonuclease A gene superfamily: evidence for a specific interaction between eosinophil-derived neurotoxin (EDN/RNase 2) and respiratory syncytial virus. Nucleic Acids Res 26: 5327-5332.
50. Shimamoto A, Kitao S, Ichikawa K, Suzuki N, Yamabe Y, et al. (1996) A unique human gene that spans over 230 kb in the human chromosome 8p11-12 and codes multiple family proteins sharing RNA-binding motifs. Proc Natl Acad Sci U S A 93: 10913-10917.
51. Kirchner J, Bevan MJ (1999) ITM2A is induced during thymocyte selection and T cell activation and causes downregulation of CD8 when overexpressed in CD4(+)CD8(+) double positive thymocytes. J Exp Med 190: 217-228.
52. Van den Plas D, Merregaert J (2004) In vitro studies on Itm2a reveal its involvement in early stages of the chondrogenic differentiation pathway. Biol Cell 96: 463-470.
53. Van den Plas D, Merregaert J (2004) Constitutive overexpression of the integral membrane protein Itm2A enhances myogenic differentiation of C2C12 cells. Cell Biol Int 28: 199-207.
54. Hunt TW, Fields TA, Casey PJ, Peralta EG (1996) RGS10 is a selective activator of G alpha i GTPase activity. Nature 383: 175-177.
55. Appleton CT, James CG, Beier F (2006) Regulator of G-protein signaling (RGS) proteins differentially control chondrocyte differentiation. J Cell Physiol 207: 735-745.
56. Moratz C, Harrison K, Kehrl JH (2004) Regulation of chemokine-induced lymphocyte migration by RGS proteins. Methods Enzymol 389: 15-32.
57. Kim SD, Sung HJ, Park SK, Kim TW, Park SC, et al. (2006) The expression patterns of RGS transcripts in platelets. Platelets 17: 493-497.
58. Eklund EA (2007) The role of HOX genes in malignant myeloid disease. Curr Opin Hematol 14: 85-89.
59. Andreeff M, Ruvolo V, Gadgil S, Zeng C, Coombes K, et al. (2008) HOX expression patterns identify a common signature for favorable AML. Leukemia.
60. Grubach L, Juhl-Christensen C, Rethmeier A, Olesen LH, Aggerholm A, et al. (2008) Gene expression profiling of Polycomb, Hox and Meis genes in patients with acute myeloid leukaemia. Eur J Haematol.
61. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, et al. (2002) Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 16: 186-195.
62. Kawagoe H, Humphries RK, Blair A, Sutherland HJ, Hogge DE (1999) Expression of HOX genes, HOX cofactors, and MLL in phenotypically and functionally defined subpopulations of leukemic and normal human hematopoietic cells. Leukemia 13: 687-698.
63. Roche J, Zeng C, Baron A, Gadgil S, Gemmill RM, et al. (2004) Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia 18: 1059-1063.
64. Thompson A, Quinn MF, Grimwade D, O'Neill CM, Ahmed MR, et al. (2003) Global down-regulation of HOX gene expression in PML-RARalpha + acute promyelocytic leukemia identified by small-array real-time PCR. Blood 101: 1558-1565.
65. Giampaolo A, Sterpetti P, Bulgarini D, Samoggia P, Pelosi E, et al. (1994) Key functional role and lineage-specific expression of selected HOXB genes in purified hematopoietic progenitor differentiation. Blood 84: 3637-3647.
66. Voso MT, Scardocci A, Guidi F, Zini G, Di Mario A, et al. (2004) Aberrant methylation of DAP-kinase in therapy-related acute myeloid leukemia and myelodysplastic syndromes. Blood 103: 698-700.
67. Hatfield KJ, Hovland R, Oyan AM, Kalland KH, Ryningen A, et al. (2008) Release of angiopoietin-1 by primary human acute myelogenous leukemia cells is associated with mutations of nucleophosmin, increased by bone marrow stromal cells and possibly antagonized by high systemic angiopoietin-2 levels. Leukemia 22: 287-293.
68. Tickenbrock L, Schwable J, Wiedehage M, Steffen B, Sargin B, et al. (2005) Flt3 tandem duplication mutations cooperate with Wnt signaling in leukemic signal transduction. Blood 105: 3699-3706.
69. Whitman SP, Ruppert AS, Radmacher MD, Mrozek K, Paschka P, et al. (2008) FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 111: 1552-1559.
70. Lopez-Pedrera C, Villalba JM, Siendones E, Barbarroja N, Gomez-Diaz C, et al. (2006) Proteomic analysis of acute myeloid leukemia: Identification of potential early biomarkers and therapeutic targets. Proteomics 6 Suppl 1: S293-299.
71. Inoue K, Sugiyama H, Ogawa H, Yamagami T, Azuma T, et al. (1994) Expression of the interleukin-6 (IL-6), IL-6 receptor, and gp130 genes in acute leukemia. Blood 84: 2672-2680.
72. Liu ZJ, Zhang Y, Zhang XB, Yang X (2004) Abnormal mRNA expression of ASPP members in leukemia cell lines. Leukemia 18: 880.
73. Rusiniak ME, Yu M, Ross DT, Tolhurst EC, Slack JL (2000) Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer Res 60: 1824-1829.
74. Heuser M, Beutel G, Krauter J, Dohner K, von Neuhoff N, et al. (2006) High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 108: 3898-3905.
75. Okabe-Kado J (2002) Serum nm23-H1 protein as a prognostic factor in hematological malignancies. Leuk Lymphoma 43: 859-867.
76. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, et al. (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103: 1901-1908.
77. Geller RB, Zahurak M, Hurwitz CA, Burke PJ, Karp JE, et al. (1990) Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 76: 340-347.
78. Fruchart C, Lenormand B, Bastard C, Boulet D, Lesesve JF, et al. (1996) Correlation between CD34 expression and chromosomal abnormalities but not clinical outcome in acute myeloid leukemia. Am J Hematol 53: 175-180.
79. Cheong JW, Eom JI, Maeng HY, Lee ST, Hahn JS, et al. (2003) Constitutive phosphorylation of FKHR transcription factor as a prognostic variable in acute myeloid leukemia. Leuk Res 27: 1159-1162.
80. Kreuter M, Woelke K, Bieker R, Schliemann C, Steins M, et al. (2006) Correlation of neuropilin-1 overexpression to survival in acute myeloid leukemia. Leukemia 20: 1950-1954.
81. Xie P, Shen YF, Shi YP, Ge SM, Gu ZH, et al. (2008) Overexpression of glucosylceramide synthase in associated with multidrug resistance of leukemia cells. Leuk Res 32: 475-480.
82. Mrozek K, Marcucci G, Paschka P, Whitman SP, Bloomfield CD (2007) Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood 109: 431-448.
83. Sauvageau G, Thorsteinsdottir U, Hough MR, Hugo P, Lawrence HJ, et al. (1997) Overexpression of HOXB3 in hematopoietic cells causes defective lymphoid development and progressive myeloproliferation. Immunity 6: 13-22.
84. Thorsteinsdottir U, Sauvageau G, Hough MR, Dragowska W, Lansdorp PM, et al. (1997) Overexpression of HOXA10 in murine hematopoietic cells perturbs both myeloid and lymphoid differentiation and leads to acute myeloid leukemia. Mol Cell Biol 17: 495-505.
85. Kroon E, Krosl J, Thorsteinsdottir U, Baban S, Buchberg AM, et al. (1998) Hoxa9 transforms primary bone marrow cells through specific collaboration with Meis1a but not Pbx1b. Embo J 17: 3714-3725.
86. Perkins A, Kongsuwan K, Visvader J, Adams JM, Cory S (1990) Homeobox gene expression plus autocrine growth factor production elicits myeloid leukemia. Proc Natl Acad Sci U S A 87: 8398-8402.
87. Borrow J, Shearman AM, Stanton VP, Jr., Becher R, Collins T, et al. (1996) The t(7;11)(p15;p15) translocation in acute myeloid leukaemia fuses the genes for nucleoporin NUP98 and class I homeoprotein HOXA9. Nat Genet 12: 159-167.
88. Kamps MP, Murre C, Sun XH, Baltimore D (1990) A new homeobox gene contributes the DNA binding domain of the t(1;19) translocation protein in pre-B ALL. Cell 60: 547-555.
89. Hatano M, Roberts CW, Minden M, Crist WM, Korsmeyer SJ (1991) Deregulation of a homeobox gene, HOX11, by the t(10;14) in T cell leukemia. Science 253: 79-82.
90. Ulrich CM, Carlson CS, Sibert J, Poole EM, Yu JH, et al. (2005) Thromboxane synthase (TBXAS1) polymorphisms in African-American and Caucasian populations: evidence for selective pressure. Hum Mutat 26: 394-395.
91. Shen RF, Tai HH (1998) Thromboxanes: synthase and receptors. J Biomed Sci 5: 153-172.
92. Moussa O, Riker JM, Klein J, Fraig M, Halushka PV, et al. (2008) Inhibition of thromboxane synthase activity modulates bladder cancer cell responses to chemotherapeutic agents. Oncogene 27: 55-62.
93. Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, et al. (2005) Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia 7: 180-189.
94. Karolchik D, Baertsch R, Diekhans M, Furey TS, Hinrichs A, et al. (2003) The UCSC Genome Browser Database. Nucleic Acids Res 31: 51-54.
95. Boyle EI, Weng S, Gollub J, Jin H, Botstein D, et al. (2004) GO::TermFinder-open source software for accessing Gene Ontology information and finding significantly enriched Gene Ontology terms associated with a list of genes. Bioinformatics 20: 3710-3715.
96. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29.